Date updated:02-23-2008
The following is a list of companies from a collection of various research reports.

-
CZN
Czn - $0.00
- N/A
- $N/A
Buy-- Price 10.94 on Feb. 19 by Hilliard Lyons CZN's 9.1% dividend yield [makes it] one of the five highest-yielding stocks in the Standard & Poor's 500... . The stock has declined by 32% from its 52-week high ... yet fundamentals [haven't] materially changed. CZN typically has an [earnings before interest, depreciation, taxes and amortization] margin in the mid-50% range, [quite high among] rural local-exchange carriers... . We expect "08 [free cash flow] of $500 million. 13 target. Market-cap: $3.7 billion.

-
FBCM
Fbr Capital Marke - $6.50
- 0.00%
- $6.49
Buy-- Price 6.69 on Feb. 20 by Think Equity FBCM reported weak 4Q results [amid] a difficult capital-markets environment and subdued capital-raising ... Investment-banking revenue fell 62% y/o/y, a 54% sequential decrease. While ... FBCM's pipeline [looks] relatively solid, challenging market conditions could continue to weigh on capital-raising activity near-term. We're lowering FY08 EPS estimate from 76 cents to 11 cents but maintain Buy. Given net cash of $6 a share and book value of $7.91 a share, we believe downside ... is limited. Target: 8 [from 15]. Market-cap: $430 million.

-
GWR
Genesee - $33.40
- +6.61%
- $32.00
Outperform-- Price 27.12 on Feb. 19 by Morgan Keegan [This leading international short-line railroad with 5,900+ track miles and another 3,700 via access arrangement] reported 4Q07 [earnings per share] of 37 cents -- beating our and management estimates... . Based on our increased fiscal-year "08 earnings estimate of $1.70 a share, GWR trades at 17.4 times... . GWR benefits from accretive acquisitions ... [plus] growth in nonfreight revenues and pricing power. Market-cap: $957 million.

-
NOVA
Novamed - $3.94
- +3.41%
- $3.86
Strong Buy-- Price 3.86 on Feb. 19 by Raymond James NovaMed reported normalized 4Q07 EPS from continuing operations of 8 cents... . Overall, 4Q results were better than expected (especially considering recent lack of enthusiasm for its shares -- trading at near-historic lows) and consistent with our recent upgrade on Jan. 25 from Outperform to Strong Buy (at $2.96), as same-facility revenue growth (+9% y/o/y) ... coupled with improved volumes in 4Q, [were seen to] act as catalysts for outperformance heading into 2008. Market-cap: $97 million.

-
RCL
Royal Caribbean C - $25.30
- +0.84%
- $25.40
Outperform-- Price 37.23 on Feb. 19 by Bear Stearns [Due to cost increases,] we are lowering our 1Q08 EPS to 27 cents (from 30 cents) and 2008 EPS to $3.22 (from $3.25). We maintain our "08 year-end target, 49, which we base on 13.5 times our 2009 EPS of $3.60. Risks relate to rising fuel expense and the impact of a slowing [of] leisure consumer[s] given continued macroeconomic weakness. Market-cap: $10.4 billion.

-
SINT
N/a - $30.92
- 0.00
- $30.92
Neutral-- Price 23.80 on Feb. 19 by Jesup & Lamont We believe IT-contractor SINT is well-positioned with the Air Force and to benefit from transformation of the military. But ... given SINT's "07 organic growth of 3.2% down from 8% in 2006, we['d] stay on the sidelines... . For 2009E we forecast EPS $1.84. Market-cap: $316.5 million.

-
TASR
Taser Internation - $4.32
- +3.10%
- $4.28
Buy-- Price 12 on Feb. 20 by Garp Research Despite a 60% jump in revenue and near doubling of EPS in 4Q07, TASR shares dropped by 10% ... in "07, TASR experienced a net decline in outstanding wrongful-death cases for the first time ever ... We think investor focus on gross margin compression is misplaced because the real story is the company's sizable operating leverage, which could lead to an incremental operating margin of 40% to 50% for "08. Market-cap: $725 million.

-
UTHR
United Therapeuti - $45.19
- -0.22%
- $45.67
Hold-- Price 88 on Feb. 19 by Brean Murray Carret [Despite] concerns regarding results of oral treprostinil pivotal trials and launch of Viveta [for pulmonary arterial hypertension], we belie[ve] treprostinil is the best-in-class therapy for PAH and expect continued growth for the Remodulin franchise in "08, despite flat quarter/over/quarter. We now forecast 1Q08-4Q08 and year-end 2008 EPS to be: 49 cents, 39 cents, 48 cents, 33 cents, and $1.69, respectively. Market-cap: $1.8 billion.
- Barron's Research Reports 2-23-2008's Blog
- No Blogs Found
- Top Professional Portfolios
- 1. Fidelity Contrafund - ...
- 2. Navellier & Associ...
- 3. Calamos Advisors
- 4. Argus Management
- 5. Robert Karr - Joho Cap...
- show all
- Top Do-It-Yourself Portfolios
- » Joseph Russell Portfolio 1
- » Albo's First Portfolio
- » Darrell Werth Portfolio 1
- » Echo5Joker's Portfolio
- » jgroov Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Roberto Pedone Posted on Dec. 4, 2009 According to Jim Cramer, the bears need a new line of argument. He said the doom-and-gloomers have been very quiet of late, but...
By Fred Fuld Posted on Dec. 3, 2009 Everyone can appreciate the security offered by a regular income, whether in the form of a paycheck or retirement check -- or a divi...
Posted on Dec. 3, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is to gather as much in...
By Roberto Pedone Posted on Dec. 3, 2009 The traders of CNBC’s “Fast Money” think the path of least resistance for the stock market remains to the upside. On Tues...
A. Penny stocks web sites are full of scam
artists. I would stay away from them and
do your own research. db
A. The only one I own : SLX,
too hard pick a winner out all of them
TheStreet Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first" approach to investing a... more
Here are the 10 stocks in the Dow Jones Industrial Average stocks with the highest yields as of the market close on Dec. 3, 2009. more
Below is a list of some of the companies that have their ex-dividend date Monday, Dec. 7, 2009. What is the ex-dividend date? The ex-dividend date of a stock is the s... more











Comments not available